{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/67105af848726944170ab1fe/6a55ece83f3beee8671702e3?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Amit Etkin: Precision Psychiatry’s Future Isn’t Genomics—It’s Brain Activity","description":"<p>For decades, psychiatry has relied on symptom-based diagnosis and trial-and-error treatment, but precision medicine is set to transform mental health care by using objective biological measures—such as EEG, sleep and circadian rhythm data, and cognitive testing—with AI-driven analysis to match patients with the therapies most likely to work for them. In this episode of <em>Behind the Breakthroughs</em>, Alto Neuroscience founder and CEO Amit Etkin explains how biomarker-guided drug development and biologically defined patient populations could make precision psychiatry routine, improving outcomes and changing how psychiatric disorders are diagnosed and treated.</p><p><br></p><p>Produced and hosted by Jonathan D. Grinstein, PhD</p><p>Audio mixed and mastered by Erick Ziegler</p><p>Brought to you by Inside Precision Medicine (SAGE Publishing)</p>","author_name":"Inside Precision Medicine"}